Harmony Biosciences (HRMY) CFO sells 3,746 shares at $37.15 avg

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. disclosed that Chief Financial Officer Sandip Kapadia sold 3,746 shares of common stock on January 26, 2026 in an open-market transaction coded as a sale. The shares were sold at a weighted average price of $37.152 under a pre-arranged Rule 10b5-1 trading plan.

After this transaction, Kapadia directly beneficially owned 24,521 shares of Harmony Biosciences common stock. The filing also notes that a previous Form 4 filed on January 26, 2026 had inadvertently misstated the post-transaction share balance, which has been corrected in this report.

Insider Trade Summary

Net Seller: 3,746 shares ($139,171)

Net Sell 1 txn

Insider Kapadia Sandip

Role CHIEF FINANCIAL OFFICER

Sold 3,746 shs ($139K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,746	$37.152	$139K

Holdings After Transaction: Common Stock — 24,521 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kapadia Sandip

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

630 W GERMANTOWN PIKE, SUITE 215

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S(1)		3,746	D	$37.152(2)	24,521(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.

	/s/ Christian Ulrich, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did Harmony Biosciences (HRMY) report for January 26, 2026?

Harmony Biosciences reported that CFO Sandip Kapadia sold 3,746 common shares on January 26, 2026. The sale was executed as an open-market transaction under a Rule 10b5-1 trading plan at a weighted average price of $37.152 per share.

How many Harmony Biosciences (HRMY) shares did the CFO sell and at what price?

CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences common stock at a weighted average price of $37.152. The filing notes the trades occurred in multiple transactions, with individual prices ranging between $36.57 and $37.70 per share.

Was the Harmony Biosciences (HRMY) CFO sale made under a Rule 10b5-1 plan?

Yes, the CFO’s sale was executed pursuant to a Rule 10b5-1 trading plan. This type of pre-arranged plan allows insiders to sell shares according to predetermined instructions, helping separate routine diversification from discretionary trading decisions.

How many Harmony Biosciences (HRMY) shares does the CFO own after the reported sale?

After selling 3,746 shares, CFO Sandip Kapadia beneficially owns 24,521 Harmony Biosciences common shares directly. This updated ownership figure corrects a previously misstated post-transaction balance disclosed in an earlier Form 4 filed on January 26, 2026.

What correction did the latest Harmony Biosciences (HRMY) Form 4 make to prior disclosures?

The latest Form 4 corrects the number of shares beneficially owned after earlier reported transactions. A previous Form 4 filed on January 26, 2026 inadvertently misstated the post-transaction holdings, and the current filing updates the correct balance to 24,521 shares.

What price range did the Harmony Biosciences (HRMY) CFO’s share sales occur within?

The CFO’s sales occurred at prices ranging from $36.57 to $37.70 per share. The reported $37.152 figure is a weighted average price across multiple individual transactions executed within that disclosed trading range.